Medicines in the making
We design no-regrets drug candidates against the most promising disease targets. Our process involves:
Matchmaking
Inhibitors, protein degraders, and antibody drug conjugates are clinically proven approaches to making new medicines. We have enabled all of these in-house, so we can choose the best approach for each target and disease.
Invention
Challenging targets require hand-built solutions. Critical research is conducted in-house at our U.S. and EU facilities.
Integration
In silico and machine learning models help our scientists understand protein targets on an atomic level, rapidly evolving chemical matter into medicines. Experimental results make better, more predictive models, helping us prioritize the best ideas.
Impact
We serve patients with hard-to-treat conditions including cancer, autoimmune and neurological diseases.